Table of contents
Development of marketing authorisation procedures for pharmaceuticals.
Interpreting clinical evidence.
International pharmaceutical policy - health creation or wealth creation?.
The development of fourth hurdle policies around the world.
Economic modelling in drug reimbursement.
Priority-setting in health care: matching decision criteria with policy objectives.
The tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral.
Relationship between stakeholders: managing the war of the words.
Medicines and the media: good information or misleading hype?.
How to promote quality use of cost-effective medicines.
Making it happen and making it sustainable.
Pricing of pharmaceuticals.
Evaluating pharmaceuticals for health policy in low and middle income country settings